Foundation · No. 01
Semaglutide
a weekly GLP-1 receptor agonist
0.25 MG → 2.4 MG · 4-week supply
First month
$179.99
≈ $6.00 / day
Brand-name Wegovy cash
$1,349
$45 / day
Fig. 01 · SemaglutideLOT 50087439
a weekly GLP-1 receptor agonist
0.25 MG → 2.4 MG · 4-week supply
Semaglutide is the first GLP-1 weight-management compound to enter wide clinical use. It is the active molecule in branded Wegovy® and Ozempic®. The HealthRX preparation is compounded by Manifest Pharmacy under Section 503A on a valid, patient-specific prescription.
Semaglutide is a long-acting synthetic analog of human GLP-1, the gut hormone released after a meal. By binding to the GLP-1 receptor, it slows gastric emptying, amplifies the body's satiety signaling in the hypothalamus, and improves glucose-dependent insulin secretion. The result is reduced appetite, quieter food noise, and gradual sustained weight loss.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 0.25 mg / week | Initiation. Lowest dose, designed to acclimate the gut. |
| Weeks 05–08 | 0.5 mg / week | First dose escalation. Most appetite changes start here. |
| Weeks 09–12 | 1.0 mg / week | Provider check-in. Re-evaluate tolerance and response. |
| Weeks 13–16 | 1.7 mg / week | Therapeutic dose for many patients. |
| Weeks 17+ | 2.4 mg / week | Maintenance dose, only if tolerated and clinically appropriate. |